Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376877 · ClinicalTrials.gov registry record · Phase 2
Connectomic Targeted TMS Target for Refractory Anxiety
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT06376877: Clinical Trial Phase 2 study, sponsored by Brigham and Women's Hospital.
NCT06376877 is a Phase 2 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376877, a Phase 2 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
We will perform a randomized sham-controlled trial of aiTBS to an anxiosomatic circuit in patients with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder). 80 participants with an anxiety-related disorder (defined below) will receive 50 active or sham TMS treatments over 5 days (following the SAINT protocol, which is FDA-cleared for MDD. The primary outcome will be the BAI, with a modified recall window to reflect the short treatment interval. Participants randomized to sham will be offered an open-label crossover extension.
Primary Outcome
21 item self-report scale that assesses anxiety symptoms, with a particular emphasis on physiological anxiety symptoms
Interventions
- PROCEDURE Transcranial magnetic stimulation
- PROCEDURE Sham transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What is known before NCT06376877 opens enrollment
NCT06376877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Transcranial magnetic stimulation is the first listed.
NCT06376877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06376877 about?
NCT06376877 is a clinical study titled "Connectomic Targeted TMS Target for Refractory Anxiety". We will perform a randomized sham-controlled trial of aiTBS to an anxiosomatic circuit in patients with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder). 80 participants with an ...
What is the current status of trial NCT06376877?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-08-01. Estimated completion is 2029-02-01.
What interventions are being tested in trial NCT06376877?
The interventions under investigation include: Transcranial magnetic stimulation (PROCEDURE), Sham transcranial magnetic stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT06376877?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06376877's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI